Business

Mass. Movers

Celldex studying kidney disease therapy

Celldex has started a pilot study on a new treatment.

istockphoto.com

Celldex has started a pilot study on a new treatment.

Shares of Celldex Therapeutics continued to rise on Friday, four days after the company said it has begun a pilot study of a treatment for a rare kidney disease called dense deposit disease. Celldex said the first patient was dosed in the study of the disease, which ultimately results in kidney failure for most patients. Celldex has its operations office in Needham and also operates a manufacturing plant in Fall River, among other facilities in the Northeast.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.